SCHEMBL5741782

SCHEMBL5741782

CCOC(=O)Cc1cc(I)c(N)c(I)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.43
CYP4Z1 Q86W10 1/20 0.40
GAA P10253 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.38
MGAM O43451 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TSHR P16473 1/20 0.37
PPIB P23284 1/20 0.37
PPIA P62937 1/20 0.37
PPID Q08752 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29185264 0.84 LMNA (0.41) SMN1; SMN2GAAALDH1A1MAPTMAPK1
SCHEMBL4597795 0.82 ALDH1A1 (0.45) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT
SCHEMBL5627469 0.80 SMN1; SMN2 (0.46) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT
SCHEMBL2131830 0.80 SMN1; SMN2 (0.46) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT
SCHEMBL17161212 0.80 SMN1; SMN2 (0.41) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT
SCHEMBL9606724 0.79 SMN1; SMN2 (0.43) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT
SCHEMBL11147975 0.79 THRB (0.46) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT
SCHEMBL19592643 0.79 ALDH1A1 (0.49) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT
SCHEMBL14676758 0.78 THRA (0.42) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT
SCHEMBL24207037 0.76 SMN1; SMN2 (0.41) SMN1; SMN2CYP4Z1GAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP disclosed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US disclosed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP disclosed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267015-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 SMN1; SMN2 2376/4885CYP4Z1 4588/4885GAA 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.